The study cohort was 59% male, with a median age of 55 years (interquartile range, 41-65 years). Median time from ECMO cannulation to first TCD examination was 1.4 (0.9-2.1) days for VA- and 3.5 (1.5-8.8) days for VV-ECMO ( P = .001, Figure 2). Reasons for not completing a TCD examination are shown in Figure 1. Conclusionsĭuring the study period, 229 consecutive patients received ECMO support, of whom 145 (63.3%) underwent at least 1 TCD examination: 100 (68.9%) patients receiving VA-ECMO underwent a total of 187 examinations, whereas 45 (31.1%) patients receiving VV-ECMO underwent a total of 65 examinations ( Figure 1). In multivariable logistic regression analyses, neither ABI nor a composite outcome of arterial thromboembolic events was associated with presence or number of MES in VA- ECMO. ABI occurred in 38% and 31.1% of patients on VA- and VV-ECMO, respectively. In both VA- and VV-ECMO, MES presence or number was not associated with presence of clot or fibrin in the ECMO circuit or with any studied hemodynamic, laboratory, or ECMO parameters at the time of TCD. Presence or number of MES was not associated with VA-ECMO cannulation mode (23.4% MES presence in peripheral cannulation vs 25.8% in central cannulation, P = .80). MES were present in 29.4% of patients on VA-ECMO without additional cardiac support, compared with 38.1% with intra-aortic balloon pump and 57.1% with left ventricular assist device, but these differences were not statistically significant ( P = .39 P = .20, respectively). MES were observed in 35 (35.0%) patients on VA-ECMO and 2 (4.7%) patients on VV-ECMO ( P < .001), corresponding to 46 (24.6%) and 2 (3.1%) TCD examinations, respectively. Of 145 patients on ECMO who underwent at least 1 TCD examination, 100 (68.9%) patients on VA-ECMO received 187 examinations whereas 45 (31.1%) patients on VV-ECMO received 65 examinations ( P = .81).
0 kommentar(er)
